FRI106 Outcomes Of SGLT2 Inhibitors In Patients With Heart Failure With Or Without Diabetes In A Tertiary Care Center In Saudi Arabia

Abstract

Abstract Disclosure: S.F. Alqifari: None. A. Mohammed: None. E. Anwar: None. K. Niazi: None. R. Aldawish: None. M. Mutlaq: None. M. Binsaqr: None. A. Khojah: None. R. Albahli: None. P. Amirthalingam: None. A. Aljabri: None. S. Ziada: None. B. Alshaye: None. S. Almlkhlef: None. Objectives: The role of Sodium-glucose cotransporter 2 (SGLT2) inhibitors in the reduction of renal complications, death, and hospitalization in patients with heart failure has been highlighted in recent trials. However, real-world evidence is lacking, especially in the Middle East. This study aims to examine SGLT2 inhibitors outcomes in patients with heart failure with or without diabetes mellitus. Materials and Methods: This is a retrospective single-center study conducted in Saudi Arabia that reviewed patients’ data from July 2021 to June 2022. We included adults (≥18 years) diagnosed with heart failure and treated with Empagliflozin for a minimum of 3 months. Results: A total of 45 patients were included in the study. A significant difference was detected among the group of patients with diabetes and no diabetes in baseline diastolic blood pressure (DBP), baseline left ventricular ejection fraction (LVEF), and the use of diabetic medications (p= 0.008, <0.001, 0.008), respectively. SGLT2 inhibitors use signaled a trend towards improvement in HbA1C, LVEF, and ED visits frequency in both groups, however, findings were non-statically significant. Conclusions: Although the use of SGLT2 inhibitors for at least 3 months improved HbA1C, LVEF, and ED visit frequency in both groups, results were not statistically significant. These findings warrant larger studies to further evaluate the clinical outcomes of SGLT2 inhibitors in Saudi patients. Presentation: Friday, June 16, 2023